{"id":198054,"name":"ALLERGAN INC (FORMERLY ACTAVIS INC )","slug":"allergan-inc-formerly-actavis-inc","state":"DC","country":"United States of America","description":"Pharmaceutical manufacturer specializing in generic, brand and biosimilar products.","totalSpending":520000,"filings":10,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":200000},{"year":2020,"income":120000}],"issues":[{"code":"PHA","display":"Pharmacy"},{"code":"CPT","display":"Copyright/Patent/Trademark"},{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"HCR","display":"Health Issues"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["THE D MAJOR GROUP"],"lobbyists":["DIANE MAJOR","BRENDA REESE"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","White House Office","Office of Management & Budget (OMB)"],"sampleDescriptions":["Monitor issues concerning bioequivalence standards for pharmaceuticals.","Advocate for Inter Partes Review (IPR) reform concerning pharmaceuticals.","Monitor technical corrections to H.R. 1, the Tax Cuts and Jobs Act.","Advocate for voluntary best practices related to pharmaceutical pricing. Engage with policymakers on Medicare Part D prescription drug benefit as related to HR 1892, the Bipartisan Budget Act of 2018.","Advocate for FDA oversight of compounded medicines as related to the HR 1625, the Consolidated Appropriations Act of 2018."]}